Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks (Q37281766)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

title

Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Barry AL

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Thornsberry C

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Washington JA 2nd

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Fass RJ

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Anhalt JP

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Neu HC

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Tilton RC

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

Painter BG

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

language of work or name

English

0 references

publication date

1 June 1985

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Microbiology

11 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

page(s)

880-883

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers

11 September 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

In vitro activity of ciprofloxacin (Bay o 9867)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Antibiotic susceptibility testing by a standardized single disk method

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Pharmacokinetics of intravenously administered ciprofloxacin

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Pharmacokinetics and tissue penetration of ciprofloxacin

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=271810

Diffusion of ciprofloxacin into prostatic fluid

26 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3159749

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dose- and sex-independent disposition of ciprofloxacin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3159749

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3159749

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json

11 September 2019

PubMed publication ID

3159749

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3159749%20AND%20SRC:MED&resulttype=core&format=json